Compare Crispr Therapeutics AG (CRSP) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Quantum Computing Inc — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: Crispr Therapeutics AG is far larger — about 2.9× Quantum Computing Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Quantum Computing Inc for 25 Days on average.
| CRSP | QUBT | |
|---|---|---|
Market Cap | $4.88B | $1.69B |
Volume | 2,861,747 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $74.92 | $21.78 |
52-Week Low | $44.34 | $6.31 |
Typical Hold Time | 77 Days | 25 Days |
Enterprise Value | $3.30B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Quantum Computing Inc. (QUBT) trades at $7.44, down 2.36% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation pose challenges.
QUBT offers significant upside potential with a consensus price target of $17.33 (133% upside) and 75% analyst buy ratings, supported by strong revenue growth and technological advancements. However, the stock carries high risk due to persistent losses, negative cash flow from operations, and execution challenges in the competitive quantum computing space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
